Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 252 participants.

Also called NCT05970679

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 252 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05970679
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05970679. Randomized; quadruple masking; primary purpose treatment. Start 2022-08-17 (actual); primary completion 2023-04-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A
Condition
Hypercholesterolemia, Dyslipidemia
Intervention (Drug)
Ezetimibe/Atorvastatin 10/5 mg
Intervention (Drug)
Atorvastatin 5mg
Intervention (Drug)
Ezetimibe 10mg
Intervention (Drug)
Atorvastatin 10mg
Intervention (Drug)
DW1125 placebo
Intervention (Drug)
DW1125A placebo
Intervention (Drug)
DW1125E placebo
Intervention (Drug)
DW1125A-1 placebo
Lead sponsor
Daewon Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05970679
Content hash
fbd0f2245252c69d05e5af40c3535eb7ae511c8629924ae03aef5de028bbf654